$IBRX

ImmunityBio is a commercial stage biotechnology company developing immunotherapies and vaccines for cancer and infectious diseases. The company’s flagship product is an immunotherapy called ANKTIVA, used especially in bladder cancer and, with recent approvals, in lung cancer treatments.
The biotechnology sector is inherently high risk, and pricing is generally tied to the approval/sales success of a single drug. ImmunityBio’s performance in recent months depends on whether Anktiva can move beyond being just an expectation and become a global product that directly writes cash into the balance sheet. This is important. Especially their expansion into more than 30 countries and their agreement with the FDA for the papillary bladder cancer application without requiring a new clinical trial keep the company’s 12–18 month story quite strong.
However, the company is still burning a significant amount of cash due to intensive R&D activities.
On the monthly chart, hit the RSI & Correction band. ..